Hospital operator Tenet Healthcare (NYSE:THC) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.3% year on year to $5.27 billion. The company’s full-year revenue guidance of $21.1 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $4.02 per share was 40.1% above analysts’ consensus estimates.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 7.8%. This drop is a far cry from the S&P 500’s 7.1% ascent.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Tenet Healthcare currently trades at $173.09 and has been a dream stock for shareholders. It’s returned 876% since July 2020, blowing past the S&P 500’s 96.3% gain. The company has also beaten the index over the past six months as its stock price is up 32.9% thanks to its solid quarterly results.
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
